Market Overview

Novavax Shares Rise 30% On Positive Data, But Risks Remain

Share:
Novavax Shares Rise 30% On Positive Data, But Risks Remain

Novavax, Inc. (NASDAQ: NVAX) popped 31 percent Wednesday evening after management announced the NanoFlu Vaccine demonstrated improved immune responses over alternative flu vaccines.

Biotech experts disputed the data’s significance, with STAT News' Adam Feuerstein confessing skepticism.

Meanwhile, Chardan analyst Keay Nakae asserted that NanoFlu compared favorably to Sanofi SA (ADR) (NYSE: SNY)’s Fluzone HD in immunogenicity.

NanoFlu was found to significantly boost hemagglutination inhibition antibody (HAI) responses against H1N1, H3N2 and B/Brisbane strains, leading to a 47-percent rate improvement; significantly boost HAI immune responses against historic and forward-drifted H3N2 strains, with respective improvements of 64 percent and 54 percent improvement; and demonstrate strong neutralizing antibody responses against three H3N2 strains.

A Risk-Weighted Thesis

Despite his optimistic read on the Phase 1/2 trial data, Nakae maintained a Neutral rating on the stock and predicted 46-percent downside.

The analyst justified his bearishness considering Novavax’s expected incurrence of near-term operating losses, potential need to raise capital, unproven pipeline, significant competition and uncertain protection of intellectual property.

“The Company has a history of losses, and may never become and remain consistently profitable,” Nakae wrote in a Thursday note. “...The Company’s product candidates are unproven and may never lead to a marketable product.”

What’s Next

Novavax expects to launch a Phase 2 trial in the third quarter.

At time of publication, shares were trading up 27 percent at $2.76.

Related Links:

More Bad News For Novavax: A Citi Downgrade

Novavax Analyst Turns Uber-Bullish, Raises Price Target To $10

Latest Ratings for NVAX

DateFirmActionFromTo
Sep 2019MaintainsOutperform
Mar 2019MaintainsBuyBuy
Feb 2019DowngradesOverweightUnderweight

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings

Posted-In: Adam Feuerstein ChardanAnalyst Color News Health Care Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (NVAX + SNY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
HSKACanaccord GenuityMaintains75.0
AVGOMorgan StanleyMaintains265.0
AMATNeedhamMaintains56.0
VOYACitigroupMaintains62.0
VCCitigroupMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

A New ETF With T. Boone Pickens' Energy Acumen

Benzinga Pro's 4 Stocks To Watch Today